Pfizer, Eli Lilly execs push back as senators scrutinize drugmakers’ telehealth moves

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.

Pharma vs Congress: The latest in telehealth talks

Eli Lilly and Pfizer have responded to senators who pressed them to share the details of their online platforms LillyDirect and PfizerForAll, seeking to determine whether the pharma giants are violating the federal anti-kickback statute when they direct patients to select telehealth platforms that may prescribe their drugs, my colleague Katie Palmer tells us.

Both companies largely ducked detailed questions about their online platforms’ financial and data-sharing terms, as well as the the providers patients can reach through the sites. Instead, they reiterated that linked telehealth providers on the platforms are not paid or influenced to prescribe their specific medications.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In